Pharmaceutical

SparingVision shares trial updates for rare eye disease gene therapies

The company is also planning to expand its Phase I/II PRODYGY lead candidate trial in retinitis pigmentosa to three more US sites.

Sep 15, 2023 - 20:00
SparingVision shares trial updates for rare eye disease gene therapies
The company is also planning to expand its Phase I/II PRODYGY lead candidate trial in retinitis pigmentosa to three more US sites.
Read the original article

Tags:

Previous Article

STAT+: In new Regeneron deal for Covid drug, White House imposes price limits fo...

Next Article

NICE recommends Idorsia’s chronic insomnia treatment for UK patients

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Machine learning biotech raises $273 million in rare successful late-stage round

STAT+: Machine learning biotech raises $273 million in ...

Sep 14, 2023

STAT+: Supreme Court pauses new limits on abortion pill, pending further review next week

STAT+: Supreme Court pauses new limits on abortion pill...

Apr 17, 2023

Risk adjusted net present value: What is the current va...

Mar 13, 2024